Amendment to the Specification

Please replace the paragraph starting at page 3, line 7, with the following amended paragraph:

Retroviral protease inhibiting compounds are useful for inhibiting HIV proteases *in vitro* and *in vivo*, and are useful for inhibiting HIV (human immunodeficiency virus) infections and for treating AIDS (acquired immunodeficiency syndrome). HIV protease inhibiting compounds typically are characterized by having poor oral bioavailability. Examples of HIV protease inhibiting compounds include ~~2S,3S,5S) 5 (N (N ((N methyl N ((2 isopropyl 4 thiazolyl)methyl)amino)carbonyl)L valinyl)amino 2 (N ((5 thiazolyl)methoxy carbonyl) amino) amino 1,6 diphenyl 3 hydroxyhexane~~ (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir);
(2S, 3S, 5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]-amino-1,6-diphenylhexane (ABT-378);
N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(l-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);
N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl] amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);
5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;
1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S,3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4- t-butylamide;
5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;
~~[1S-[1R-(R-),2S*]) N[1] [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino] 2-hydroxy-1 (phenylmethyl)propyl] 2-[(2quinolinylcarbonyl)amino] butanediamide~~
[1S-[1R-(R-),2S*]-N[1] [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;
VX-478; DMP-323; DMP-450; AG1343 (nelfinavir); BMS 186,318; SC-55389a; BILA 1096 BS; and U-140690, or combinations thereof.

Please replace the paragraph starting at page 11, line 3, with the following amended paragraph:

One aspect of the instant invention provides a solid dispersion of a compound of formula I



I

A compound of formula I is an HIV protease inhibitor marketed by Abbott Laboratories under the tradename Norvir®, with the common name ritonavir [~~(2S,3S,5S) 5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl) methyl)amino)carbonyl) L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino) amino-1,6-diphenyl-3-hydroxyhexane~~ (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane]. This and other compounds as well as methods for preparing the same are disclosed in U.S. Patent Nos. 5,648,497 and 5,541,206, the disclosures of which are herein incorporated by reference.